[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-334466-105":59,"doc-detail-334466-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","targeting-cd24siglec-10-signal-pathway-for-cancer-immunotherapy-recent-advances-and-future-directions","Targeting CD24/Siglec-10 signal pathway for cancer immunotherapy - recent advances and future directions","","CD24 is a small, heavily glycosylated protein expressed on many immune cells and highly on most cancer cells, making it a key biomarker in solid tumors. Tumor-associated macrophages express Siglec-10, and interaction between Siglec-10 and CD24 on innate immune cells can dampen inflammatory signaling. By blocking CD24 binding effects that involve SHP-1/SHP-2 phosphatases and macrophage phagocytosis, CD24–Siglec-10 can prevent toll-like receptor–mediated inflammation. The review links this innate immune checkpoint to immune checkpoint inhibitor success and summarizes current CD24/Siglec-10-targeted immunotherapy progress, with future directions inferred from preclinical and clinical trial results.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/targeting-cd24siglec-10-signal-pathway-for-cancer-immunotherapy-recent-advances-and-future-directions/334466/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/targeting-cd24siglec-10-signal-pathway-for-cancer-immunotherapy-recent-advances-and-future-directions/334466.png","ImageObject",300,407,{"name":92,"@type":93},"Logic","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-10","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":52},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What roles do CD24 and Siglec-10 play in cancer-associated immune regulation?","Question",{"text":112,"@type":113},"CD24 is highly expressed in many cancer cells and on various immune cells. Siglec-10 is highly expressed by tumor-associated macrophages, and CD24–Siglec-10 interactions can reduce inflammatory responses.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How can blocking or targeting CD24/Siglec-10 influence inflammation and immune signaling?",{"text":117,"@type":113},"CD24 binding involving SHP-1 and/or SHP-2 phosphatases, as well as macrophage phagocytosis, can contribute to inflammatory signaling. CD24–Siglec-10 targeting is described as preventing toll-like receptor–mediated inflammation and modulating innate immune activity.",{"name":119,"@type":110,"acceptedAnswer":120},"Why is CD24/Siglec-10 considered relevant to cancer immunotherapy, including immune checkpoint inhibitors?",{"text":121,"@type":113},"Immune checkpoint inhibitors have shown strong antitumor activity, yet some patients relapse due to acquired resistance mechanisms. CD24 is presented as a prominent innate immune checkpoint, and the CD24/Siglec-10 axis is proposed as a useful target, with ongoing progress in related preclinical and clinical research.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},334466,1790168525,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":52,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":4},1099513958762,"https://ap-avatar.wpscdn.com/avatar/1000023916a998db790?x-image-process=image/resize,m_fixed,w_180,h_180&k=1784791008015729253","Cancer Immunology, Immunotherapy (2024) 73:31 [https://doi.org/10.1007/s00262-023-03606-0](https://doi.org/10.1007/s00262-023-03606-0)  \nTargeting CD24/Siglec‑10 signal pathway for cancer immunotherapy: recent advances and future directions  \nXingchen Li1,2 · Wenzhi Tian3 · Zhongxing Jiang1 · Yongping Song1 · Xiangyang Leng2 · Jifeng Yu1,4  \nReceived: 2 July 2023 / Accepted: 7 December 2023 / Published online: 27 January 2024 © The Author(s) 2024  \nAbstract  \nThe small, heavily glycosylated protein CD24 is primarily expressed by many immune cells and is highly expressed mostly in cancer cells. As one of the most crucial biomarkers of cancers, CD24 is frequently highly expressed in solid tumors, while tumor-associated macrophages express Siglec-10 at high levels, Siglec-10 and CD24 can interact on innate immune cells to lessen inflammatory responses to a variety of disorders. Inhibiting inflammation brought on by SHP-1 and/or SHP-2 phosphatases as well as cell phagocytosis by macrophages, the binding of CD24 to Siglec-10 can prevent toll-like receptormediated inflammation. Targeted immunotherapy with immune checkpoint inhibitors (ICI) has lately gained popularity as one of the best ways to treat different tumors. CD24 is a prominent innate immune checkpoint that may be a useful target for cancer immunotherapy. In recent years, numerous CD24/Siglec-10-related research studies have made tremendous progress. This study discusses the characteristics and workings of CD24/Siglec-10-targeted immunotherapy and offers a summary of current advances in CD24/Siglec-10-related immunotherapy research for cancer. We then suggested potential directions for CD24-targeted immunotherapy, basing our speculation mostly on the results of recent preclinical and clinical trials.  \nKeywords CD24 · Siglec-10 · Signaling pathway · Monoclonal antibody · Cancer immunotherapy  \nAbbreviations  \nADCC Antibody-dependent cellular cytotoxicity  \nADCP Antibody-dependent cell phagocytosis  \nBART Binder of arl two  \nBiTEs Bispecific T-cell engagers  \nBLPD B cell lymphoproliferative disorder  \nBMT Bone marrow transplantation  \nBRCA Breast invasive carcinoma  \nCAR-T Chimeric antigen receptor T  \nCD24 Cluster of differentiation 24  \n* Xiangyang Leng [lengxiangy@163.com](lengxiangy@163.com)  \n* Jifeng Yu [Yujifengzzu@163.com](Yujifengzzu@163.com)  \n1 The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China  \n2 Affiliated Hospital of Changchun University of Traditional Chinese Medicine, Changchun 130021, Jilin, China  \n3 ImmuneOnco Biopharmaceuticals (Shanghai) Inc., Shanghai 201203, China  \n4 Henan International Joint Laboratory of Nuclear Protein Gene Regulation, Henan University College of Medicine, Kaifeng 475004, Henan, China  \nCEL Celastrol  \nceRNA Competitive endogenous RNA  \ncfDNA Cell-free DNA  \nCIK Cytokine-induced killer  \nCK4 Cytokeratin 4  \nCRT Calreticulin  \nCSCs Cancer stem cells  \nCTCs Circulating tumor cells  \nCTLA-4 Cytotoxic T-lymphocyte-associated protein  \n4  \nDAMP Danger-associated molecular pattern  \nDLBCL Diffuse large B-cell lymphoma  \nEvs Extracellular vesicles  \nGPI Glycosylphosphatidylinositol  \nGVHD Graft-versus-host disease  \nHCC Hepatocellular carcinoma  \nHDAC Histone deacetylase  \nHIF1α Hypoxia-inducible factor-1alpha  \nHMGB1 High-mobility group box 1  \nHSA Heat-stable antigen  \nHSCT Hematopoietic stem cell transplantation  \nICIs Immune checkpoint inhibitors  \nIgG1 Immunoglobulin G1  \nirAEs Immune-related adverse events  \nITIMs  \nL1CAM  \nL1-CAM  \nLAG3  \nmAbs  \nMCL  \nNAFLD  \nNCAM  \nNSCLC  \nOC  \nPARP1  \nPD-1/PD-L1  \nSiglec-10  \nSIRPa  \nTAM  \nTME  \nTNBC  \nImmunoreceptor tyrosine-based inhibition motifs  \nL1 cell adhesion molecule  \nL1-cell adhesion molecule Lymphocyte activating gene 3  \nMonoclonal antibody Mantle cell lymphoma  \nNon-alcoholic fatty liver disease Neural cell adhesion molecule Non-small cell lung cancer Ovarian cancer  \nPoly(ADP-ribose) polymerase 1  \nProgrammed death-1/programmed death ligand-1  \nSialic","cbCaihAl71hyxoCt","https://ap.wps.com/l/cbCaihAl71hyxoCt","pdf",542101,11,"English","# Abstract\n# Keywords\n# Abbreviations\n# Introduction","[{\"question\":\"What roles do CD24 and Siglec-10 play in cancer-associated immune regulation?\",\"answer\":\"CD24 is highly expressed in many cancer cells and on various immune cells. Siglec-10 is highly expressed by tumor-associated macrophages, and CD24–Siglec-10 interactions can reduce inflammatory responses.\"},{\"question\":\"How can blocking or targeting CD24/Siglec-10 influence inflammation and immune signaling?\",\"answer\":\"CD24 binding involving SHP-1 and/or SHP-2 phosphatases, as well as macrophage phagocytosis, can contribute to inflammatory signaling. CD24–Siglec-10 targeting is described as preventing toll-like receptor–mediated inflammation and modulating innate immune activity.\"},{\"question\":\"Why is CD24/Siglec-10 considered relevant to cancer immunotherapy, including immune checkpoint inhibitors?\",\"answer\":\"Immune checkpoint inhibitors have shown strong antitumor activity, yet some patients relapse due to acquired resistance mechanisms. CD24 is presented as a prominent innate immune checkpoint, and the CD24/Siglec-10 axis is proposed as a useful target, with ongoing progress in related preclinical and clinical research.\"}]","Targeting CD24/Siglec-10 signal pathway for cancer immunotherapy - recent advances and future directions | PDF",1790006768,28]